Tag: nonHodgkin

Pharma / Biotech

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Newsemia
Related Articles Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. Ann Oncol. 2020...
Latest News

Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio

Newsemia
PARIS–(BUSINESS WIRE)–Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI┬« from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World